<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Celltrion Begins Global Phase 3 Clinical Trial for Its Bevacizumab Biosimilar &#8216;CT-P16&#8217;	</title>
	<atom:link href="https://www.novumpr.nl/2018/08/10/celltrion-begins-global-phase-3-clinical-trial-for-its-bevacizumab-biosimilar-ct-p16/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2018/08/10/celltrion-begins-global-phase-3-clinical-trial-for-its-bevacizumab-biosimilar-ct-p16/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=celltrion-begins-global-phase-3-clinical-trial-for-its-bevacizumab-biosimilar-ct-p16</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Fri, 10 Aug 2018 07:59:29 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
